Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 901–1,000 of 1,007
The PALGA group, Verschoor, A. J., Bovée, J. V. M. G., Overbeek, L. I. H., Hogendoorn, P. C. W., & Gelderblom, H. A. J. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2285-x · Cited by 65
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Li, B., Chen, H., Yang, S., Chen, F., Xu, L., Li, Y., Li, M., Zhu, C., Shao, F., Zhang, X., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01770-6 · Cited by 69
Astolfi, A., Urbini, M., Indio, V., Nannini, M., Genovese, C. G., Santini, D., Saponara, M., Mandrioli, A., Ercolani, G., Brandi, G., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1982-6 · Cited by 61
Fujimoto, Y., Akiyoshi, T., Konishi, T., Nagayama, S., Fukunaga, Y., & Ueno, M. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1769-7 · Cited by 57
Chiang, N., Chen, L., Tsai, C., & Chang, J. S.-M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-102 · Cited by 62
Park, S., Ryu, M., Ryoo, B., Park, Y. S., Sohn, B. S., Kim, H. J., Kim, C. W., Kim, K., Yu, C. S., Yook, J. H., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3866-4 · Cited by 57
Li, Y., Yang, H., Luo, R.-Z., Zhang, Y., Li, M., Wang, X., & Jia, W.-H. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.12.012 · Cited by 58
Bischof, D. A., Kim, Y., Dodson, R. M., Jimenez, M. C., Behman, R. S., Cocieru, A., Blazer, D. G., Fisher, S. B., Squires, M. H., Kooby, D. A., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3733-3 · Cited by 60
Genetics and genomics of melanoma
Ghosh, P., & Chin, L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.2 · Cited by 72
Therapeutic Implications of KIT in Melanoma
Postow, M. A., & Carvajal, R. D. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b2404 · Cited by 57
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
Tonyalı, Ö., Çoşkun, U., Yıldız, R., Karakan, T., Demırcı, U., Akyürek, N., Beneklı, M., & Buyukberber, S. (2009) · Medical Oncology · doi:10.1007/s12032-009-9284-y · Cited by 57
Updates on the Management of Gastrointestinal Stromal Tumors
Bamboat, Z. M., & DeMatteo, R. P. (2012) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2011.12.004 · Cited by 60
Targeted therapies of cancer: Angiogenesis inhibition seems not enough
Roodink, I., & Leenders, W. P. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.004 · Cited by 62
Crompton, B. D., Carlton, A. L., Thorner, A. R., Christie, A. L., Du, J., Calicchio, M. L., Rivera, M. N., Fleming, M. D., Kohl, N. E., Kung, A. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1944 · Cited by 61
Management of Gastrointestinal Stromal Tumors
Keung, E. Z.-Y., & Raut, C. P. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.12.001 · Cited by 62
Turning promiscuous kinase inhibitors into safer drugs
Zhang, X., Crespo, A., & Fernández, A. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.02.008 · Cited by 58
Raut, C. P., Morgan, J. A., & Ashley, S. W. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32802086d0 · Cited by 63
Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies
Benjamin, R. S., Blanke, C. D., Blay, J., Bonvalot, S., & Eisenberg, B. L. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-9 · Cited by 57
Self-citationLangley, R. R., Fan, D., Tsan, R. Z., Rebhun, R. B., He, J., Kim, S.-J., & Fidler, I. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3863 · Cited by 57
Nemunaitis, J. J., Bauer, S., Blay, J., Choucair, K., Gelderblom, H. A. J., George, S., Schöffski, P., von Mehren, M., Zalcberg, J. R., Achour, H., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0633 · Cited by 56
Self-citationETV6–NTRK3 as a therapeutic target of small molecule inhibitor PKC412
Thanh, H., Lý, B. T. K., Kano, Y., Tojo, A., Watanabe, T., & Sato, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.087 · Cited by 56
Rutkowski, P. L., Woźniak, A., Dêbiec‐Rychter, M., Kąkol, M., Dziewirski, W., Zdzienicki, M., Ptaszyński, K., Jurkowska, M., Limon, J., & SIEDLECKI, J. A. (2011) · Cancer · doi:10.1002/cncr.26079 · Cited by 56
Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway
PATEL, S. R. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0316-6 · Cited by 57
Mali, R. S., Ma, P., Zeng, L., Martin, H., Ramdas, B., He, Y., Sims, E. K., Nabinger, S. C., Ghosh, J., Sharma, N., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375873 · Cited by 64
Maleddu, A., Pantaleo, M. A., Nannini, M., & Biasco, G. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-75 · Cited by 56
Rusakiewicz, S., Perier, A., Semeraro, M., Pitt, J. M., von Strandmann, E. P., Reiners, K. S., Aspeslagh, S., Pipéroglou, C., Vely, F., Ivagnès, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1137418 · Cited by 64
Therapeutic implications of germline genetic findings in cancer
Thavaneswaran, S., Rath, E. M., Tucker, K., Joshua, A. M., Hess, D., Pinese, M., Ballinger, M. L., & Thomas, D. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0179-3 · Cited by 59
Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)—review and perspectives
Laurent, M., Brahmi, M., Dufresne, A., Méeus, P., Karanian, M., Ray-Coquard, I. L., & Blay, J. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.03.07 · Cited by 62
Levine, R. L., Wadleigh, M., Sternberg, D., Wlodarska, I., Galinsky, I. A., Stone, R. M., DeAngelo, D. J., Gilliland, D. G., & Cools, J. (2004) · Leukemia · doi:10.1038/sj.leu.2403548 · Cited by 56
Kim, H., Lee, J. M., Kim, S. H., Kim, K. W., Min-Jin, L., Kim, Y. J., Han, J. K., & Choi, B. I. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.6.1821463 · Cited by 56
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Gastrointestinal stromal tumours (GIST) – 17 years experience from Mid Trent Region (United Kingdom)
Ahmed, I., Welch, N. T., & Parsons, S. L. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.01.006 · Cited by 56
Ray-Coquard, I. L., Cesne, A. L., Whelan, J., Schöffski, P., Bui, B., Verweij, J., Marreaud, S. I., Glabbeke, M. M. V., Hogendoorn, P. C. W., & Blay, J. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0065 · Cited by 56
C-KIT EXPRESSION IN SARCOMATOID RENAL CELL CARCINOMA: POTENTIAL THERAPY WITH IMATINIB
Castillo-Martín, M., Petit, A., Mellado, B., Palacı́n, A., Alcover-Garcia, J. B., & Mallofré, C. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000127727.33232.cf · Cited by 56
Rubin, B. P. (2007) · Skeletal Radiology · doi:10.1007/s00256-006-0249-3 · Cited by 56
Grignani, G., Palmerini, E., Stacchiotti, S., Boglione, A., Ferraresi, V., Frustaci, S., Comandone, A., Casali, P. G., Ferrari, S., & Aglietta, M. (2010) · Cancer · doi:10.1002/cncr.25632 · Cited by 57
Yeh, C., Chen, T.-W., Tseng, J., Liu, Y., Wang, S., Tsai, C., Chiang, K., Hwang, T., Jan, Y.-Y., & Chen, M. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21630 · Cited by 55
Kang, Y.-K., Yoo, C., Ryoo, B.-Y., Lee, J. J., Tan, E., Park, I., Park, J. H., Choi, Y. J., Jo, J., Ryu, J.-S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.594 · Cited by 56
Angiogenesis and melanoma - from basic science to clinical trials.
Emmett, M. S., Dewing, D., & Pritchard‐Jones, R. (2011) · Europe PMC (PubMed Central) · Cited by 69
Serrano, C., Vivancos, A., López-Pousa, A., Matito, J., Mancuso, F. M., Valverde, C., Quiroga, S., Landolfi, S., Castro, S., Dopazo, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6597-x · Cited by 54
Self-citationHofer, M. D., Fecko, A., Shen, R., Setlur, S. R., Pienta, K. J., Tomlins, S. A., Chinnaiyan, A. M., & Rubin, M. A. (2004) · Neoplasia · doi:10.1593/neo.04157 · Cited by 58
PET: a revolution in medical imaging
Alavi, A. A., Lakhani, P. C., Mavi, A., Kung, J. W., & Zhuang, H. (2004) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.08.012 · Cited by 55
Penel, N., Delcambre, C., Durando, X., Clisant, S., Hebbar, M., Négrier, S., Fournier, C., Isambert, N., Mascarelli, F., & Mouriaux, F. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9143-2 · Cited by 60
Tefferi, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00559.x · Cited by 58
Hägerkvist, R., Jansson, L. E., & Welsh, N. (2007) · Clinical Science · doi:10.1042/cs20070122 · Cited by 54
den Abbeele, A. D. V., Gatsonis, C. G., de Vries, D. J., Melenevsky, Y. V., Szot-Barnes, A., Yap, J. T., Godwin, A. K., Rink, L. A., Huang, M., Blevins, M. L., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094425 · Cited by 54
Self-citationImatinib and Beyond in Gastrointestinal Stromal Tumors: A Radiologist's Perspective
Tirumani, S. H., Jagannathan, J. P., Krajewski, K. M., Shinagare, A. B., Jacene, H. A., & Ramaiya, N. H. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.10003 · Cited by 54
Lee, H. E., Kim, M., Lee, H. S., Lee, B. L., & Kim, W. H. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.052225 · Cited by 54
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Rink, L. A., Skorobogatko, Y. V., Kossenkov, A. V., Belinsky, M. G., Pajak, T. J., Heinrich, M. C., Blanke, C. D., von Mehren, M., Ochs, M. F., Eisenberg, B. L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0193 · Cited by 59
Self-citationPharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib
Blay, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp291 · Cited by 54
Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis
Nishioka, Y., Azuma, M., Kishi, M., & Aono, Y. (2013) · The Journal of Medical Investigation · doi:10.2152/jmi.60.175 · Cited by 58
Indications for surgery in advanced/metastatic GIST
Ford, S., & Gronchi, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.019 · Cited by 59
Classification of gastrointestinal stromal tumor syndromes
Gopie, P., Mei, L., Faber, A. C., Grossman, S. R., Smith, S. C., & Boikos, S. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0329 · Cited by 59
Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion
Nakada, M., Kita, D., Teng, L., Pyko, I. V., Watanabe, T., Hayashi, Y., & Hamada, J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4719-7_8 · Cited by 57
Pache, M., Glatz, K., B�sch, D., Dirnhofer, S., Mirlacher, M., Simon, R., Schraml, P., Rufle, A., Flammer, J., Sauter, G., et al. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0883-2 · Cited by 58
Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy
Rossi, G., Cavazza, A., Marchioni, A., Migaldi, M., Bavieri, M., Facciolongo, N. C., Petruzzelli, S., Longo, L., Tamberi, S., & Crinò, L. (2003) · Modern Pathology · doi:10.1097/01.mp.0000089780.30006.de · Cited by 54
Optimizing Diagnosis, Staging, and Management of Gastrointestinal Stromal Tumors
Gutierrez, J. C., Oliveira, L. O. P. D., Perez, E. A., Rocha-Lima, C. S., Livingstone, A. S., & Koniaris, L. G. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.04.002 · Cited by 54
Hughes, B. G. M., Yip, D., Goldstein, D., Waring, P. M., Beshay, V., & Chong, G. C. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-74 · Cited by 54
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Nakano, K., & Takahashi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030739 · Cited by 58
Machlenkin, S., Pinsk, I., Tulchinsky, H., Ziv, Y., Sayfan, J., Duek, D., Rabau, M., & Walfisch, S. (2010) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02442.x · Cited by 59
Cho, S., Kitadai, Y., Yoshida, S., Tanaka, S., Yoshihara, M., Yoshida, K., & Chayama, K. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.6.1361 · Cited by 61
Steed, H. L., Oza, A. M., Chapman, W. B., Yaron, M., & Petrillo, D. D. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.014319.x · Cited by 53
Dumont, A. G., Rink, L. A., Godwin, A. K., Miettinen, M., Joensuu, H., Strosberg, J., Gronchi, A., Corless, C. L., Goldstein, D., Rubin, B. P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr442 · Cited by 54
Self-citationDudeck, O., Zeile, M., Reichardt, P., & Pink, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq696 · Cited by 53
The Evolution of Imaging in Cancer: Current State and Future Challenges
Higgins, L., & Pomper, M. G. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.11.010 · Cited by 60
Ciavarella, S., Milano, A., Dammacco, F., & Silvestris, F. (2010) · BioDrugs · doi:10.2165/11530830-000000000-00000 · Cited by 65
Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
Shankar, L. K., den Abbeele, A. V., Yap, J. T., Benjamin, R. S., Scheutze, S., & FitzGerald, T. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2030 · Cited by 53
MacConaill, L. E., Van Hummelen, P., Meyerson, M., & Hahn, W. C. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0110 · Cited by 54
Li, G. Z., & Raut, C. P. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s180763 · Cited by 55
Ghapanvari, M., Madrakian, T., Afkhami, A., & Ghoorchian, A. (2020) · Journal of Applied Electrochemistry · doi:10.1007/s10800-019-01388-x · Cited by 53
Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec)
Esmaeli, B., Diba, R., Ahmadi, M., Saadati, H. G., Faustina, M., Shepler, T. R., Talpaz, M., Fraunfelder, R. W., Rios, M. B., & Kantarjian, H. M. (2004) · Eye · doi:10.1038/sj.eye.6701315 · Cited by 55
Perez, E. A., Gutierrez, J. C., Jin, X., Lee, D. J., Rocha-Lima, C. S., Livingstone, A. S., Franceschi, D., & Koniaris, L. G. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-006-0072-0 · Cited by 54
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
Sandström, M., Johansson, M., Andersson, U., Bergh, A. R. J., Bergenheim, A. T., & Henriksson, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602108 · Cited by 53
Are there any prognostic factors for small intestinal stromal tumors?
Bucher, P., Taylor, S., Villiger, P. M., Morel, P., & Brundler, M. A. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.09.010 · Cited by 53
Management of Gastrointestinal Stromal Tumors
Hueman, M. T., & Schulick, R. D. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.03.001 · Cited by 53
Genomic Approaches to Lung Cancer
Thomas, R. K., Weir, B. A., & Meyerson, M. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0098 · Cited by 59
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
Jiao, Y., Ou, W., Meng, F., Hai‐Meng, Z. H. O. U., & Wang, A. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-125 · Cited by 61
Molecularly Targeted Therapy: Have the Floodgates Opened?
Druker, B. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-357 · Cited by 59
Self-citationJia, P., Jin, H., Meador, C. B., Xia, J., Ohashi, K., Liu, L., Pirazzoli, V., Dahlman, K. B., Politi, K. A., Michor, F., et al. (2013) · Genome Research · doi:10.1101/gr.152322.112 · Cited by 54
Role of α1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice
Azuma, M., Nishioka, Y., Aono, Y., Inayama, M., Makino, H., Kishi, J., Shono, M., Kinoshita, K., Uehara, H., Ogushi, F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-178oc · Cited by 53
Spigel, D. R., Hainsworth, J. D., Simons, L., Meng, C., Burris, H. A., Yardley, D. A., Grapski, R., Schreeder, M. T., Mallidi, P. V., & Greco, F. A. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31814617b7 · Cited by 52
Acral myxoinflammatory fibroblastic sarcomas: are they all low‐grade neoplasms?
Hassanein, A. M., Atkinson, S. P., Al‐Quran, S. Z., Jain, S. M., & Reith, J. D. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2007.00789.x · Cited by 52
Targeted drug therapy for meningiomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2007) · Neurosurgical FOCUS · doi:10.3171/foc-07/10/e12 · Cited by 58
Pazopanib, a new therapy for metastatic soft tissue sarcoma
Verweij, J., & Sleijfer, S. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780030 · Cited by 52
Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor
Kim, T. S., Cavnar, M. J., Cohen, N. A., Sorenson, E. C., Greer, J. B., Seifert, A. M., Crawley, M. H., Green, B. L., Popow, R., Pillarsetty, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3033 · Cited by 52
Singh, A. S., Hecht, J. R., Rosen, L., Wainberg, Z. A., Wang, X., Douek, M., Hagopian, A., Andes, R., Sauer, L., Brackert, S. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0878 · Cited by 56
Histological features of acute hepatitis after imatinib mesylate treatment
James, C., Trouette, H., Marit, G., Cony‐Makhoul, P., & Mahon, F. (2003) · Leukemia · doi:10.1038/sj.leu.2402910 · Cited by 59
Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases
Koay, M. H. E., Goh, Y.-W., Iacopetta, B. J., Grieu, F., Segal, A., Sterrett, G. F., Platten, M., & Spagnolo, D. V. (2005) · Pathology · doi:10.1080/00313020400023628 · Cited by 52
Iesalnieks, I., Rümmele, P., Dietmaier, W., Jantsch, T., Zülke, C., Schlitt, H. J., Hofstädter, F., & Anthuber, M. (2005) · American Journal of Clinical Pathology · doi:10.1309/akk3-vff6-10cw-m566 · Cited by 56
The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution
Tos, A. P. D. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0782-6 · Cited by 52
Serrano, C., Bauer, S., Gómez-Peregrina, D., Kang, Y., Jones, R. L., Rutkowski, P. L., Mir, O., Heinrich, M. C., Tap, W. D., Newberry, K. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.006 · Cited by 59
Self-citationSun, X., Zhang, Q., Lin, X., Shu, P., Gao, X., & Shen, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06300-2 · Cited by 60
Tang, L., Zhang, X. P., Sun, Y., Shen, L., Li, J., Qi, L., & Cui, Y. (2010) · Radiology · doi:10.1148/radiol.10100402 · Cited by 51
The background, discovery and clinical development of BCR-ABL inhibitors
Lambert, G. K., Duhme‐Klair, A., Morgan, T., & Ramjee, M. K. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.001 · Cited by 51
Effect of antacid on imatinib absorption
Sparano, B. A., Egorin, M. J., Parise, R. A., Walters, J., Komazec, K. A., Redner, R. L., & Beumer, J. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0778-7 · Cited by 54
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Traer, E., Javidi-Sharifi, N., Agarwal, A., Dunlap, J., English, I., Martinez, J., Tyner, J. W., Wong, M., & Druker, B. J. (2014) · Blood · doi:10.1182/blood-2013-07-518381 · Cited by 53
Self-citationSalti, G. I., Ailabouni, L. D., & Undevia, S. D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2240-7 · Cited by 51
Treglia, G., Mirk, P., Stefanelli, A., Rufini, V., Giordano, A., & Bonomo, L. (2012) · Clinical Imaging · doi:10.1016/j.clinimag.2011.08.012 · Cited by 51
Oral lichenoid eruption secondary to imatinib (Glivec®)
Ena, P., Chiarolini, F., Siddi, G., & Cossu, A. (2004) · Journal of Dermatological Treatment · doi:10.1080/09546630410015556 · Cited by 51
Komita, H., Koido, S., Hayashi, K., Kan, S., Ito, M., Kamata, Y., Suzuki, M., & Homma, S. (2015) · Oncology Reports · doi:10.3892/or.2015.4149 · Cited by 52
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.